Parsaclisib

Drug Overview

Parsaclisib is an advanced, experimental cancer medication. It belongs to a highly specialized category of treatments known as Targeted Therapy. Unlike traditional chemotherapy, which attacks all fast-growing cells in the body, targeted therapies are designed to find and block specific signals that cancer cells use to survive and grow. Currently, parsaclisib is being studied in clinical trials and is not yet available at standard pharmacies.

• Generic Name: Parsaclisib
• US Brand Names: None (Investigational drug)
• Drug Class: PI3K-delta Inhibitor (Targeted Therapy)
• Route of Administration: Oral (Taken by mouth as a tablet)
• FDA Approval Status: Not FDA Approved. (In early 2022, the manufacturer voluntarily withdrew its applications for certain lymphomas in the US due to requests for further randomized trials. It remains strictly limited to clinical trials, primarily for a bone marrow cancer called myelofibrosis.)

What Is It and How Does It Work? (Mechanism of Action)

Parsaclisib is a Targeted Therapy designed to break a specific communication system inside certain types of blood cells. To understand how it works at the molecular level, it helps to look at how cells receive survival instructions.

Inside our white blood cells (specifically B-cells), there is a communication pathway called PI3K (Phosphoinositide 3-kinase). You can think of this pathway as a relay race that passes growth signals to the cell’s center. The PI3K system has different parts, and one specific part is called the “delta” isoform.

In many blood cancers, this PI3K-delta signal gets stuck in the “on” position. It constantly tells the cancer cells to grow, multiply, and hide from the body’s natural immune system.

Here is how parsaclisib steps in:

• High-Precision Blockade: Parsaclisib is a highly selective inhibitor. It specifically targets and binds to the PI3K-delta protein, acting like a roadblock.
• Cutting the Signal: By blocking this protein, the drug stops the relay race. The cancer cell no longer receives the signal to survive.
• Cellular Death (Apoptosis): Without these vital growth instructions, the cancer cell’s life cycle stops, and it undergoes a natural process of self-destruction known as apoptosis.

FDA Approved Clinical Indications

Because parsaclisib is an experimental medicine, it has not received approval from the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general public use.

Oncological Uses (Investigational Only):

• Myelofibrosis (A rare bone marrow cancer, currently tested in combination with another drug called ruxolitinib)
• Follicular Lymphoma (FL)
• Marginal Zone Lymphoma (MZL)
• Mantle Cell Lymphoma (MCL)

Non-oncological Uses:

• None at this time.

Dosage and Administration Protocols

Because parsaclisib is currently utilized in clinical trials, the exact dosage depends on the specific study rules and the type of cancer being treated. The information below reflects the dosages most commonly used during recent human trials (like the CITADEL and LIMBER studies).

Note: Individual dosing is strictly controlled by clinical trial guidelines and close medical supervision.

Clinical Efficacy and Research Results

Recent clinical data (published between 2020 and 2024) shows how parsaclisib has performed in human trials.

• Lymphoma Trials (CITADEL Studies): In Phase 2 trials for patients with relapsed Follicular Lymphoma, parsaclisib showed very strong tumor-shrinking abilities. Approximately 77% of patients had a positive response (Objective Response Rate), and the cancer was kept from growing for a median of about 15.8 months (Progression-Free Survival). However, due to the FDA requiring larger, randomized trials to ensure long-term safety for this drug class, these specific applications were withdrawn.
• Myelofibrosis Trials (LIMBER Studies): Current research (2023-2025) heavily focuses on myelofibrosis. In these Phase 2/3 trials, parsaclisib is added to a standard drug called ruxolitinib for patients who are not getting enough relief. Early results show that adding parsaclisib helps significantly shrink enlarged spleens (a major problem in this disease) and greatly reduces disease symptoms like bone pain, night sweats, and fatigue compared to using ruxolitinib alone.

Safety Profile and Side Effects

Like all medicines that alter the immune system, PI3K inhibitors like parsaclisib can cause noticeable side effects. Because it changes how white blood cells work, it can increase the risk of inflammation and infections.

Black Box Warning:

There is currently no FDA “Black Box Warning” because the drug is investigational and unapproved. However, other approved drugs in this specific class carry warnings for severe infections, diarrhea, and liver toxicity.

Common Side Effects (Occurs in >10% of patients)

• Loose stools (Diarrhea)
• Feeling unusually tired or weak (Fatigue)
• Upset stomach (Nausea)
• Skin rashes
• Cough and mild respiratory tract infections

Serious Adverse Events

• Severe Intestinal Inflammation (Colitis): Severe, persistent diarrhea that can damage the bowel.
• Liver Toxicity (Hepatotoxicity): A sharp spike in liver enzymes, meaning the liver is inflamed or stressed.
• Low White Blood Cells (Neutropenia): A drop in infection-fighting cells, making the patient highly vulnerable to severe or unusual infections.
• Lung Inflammation (Pneumonitis): Non-infectious swelling of the lung tissue that causes severe shortness of breath.

Management Strategies

• For Diarrhea and Colitis: Patients must report diarrhea immediately. Doctors may pause the trial drug and prescribe steroids to calm the intestines.
• For Liver Stress: Routine blood tests are required. If liver numbers rise, the drug is stopped until the liver heals.
• For Infection Risk: Doctors may prescribe preventive antibiotics or antiviral pills to protect the patient while their immune system is altered by the trial drug.

Research Areas

While there is no direct connection to mainstream stem cell therapies yet, the research surrounding parsaclisib is highly relevant to the “tumor microenvironment.” In myelofibrosis, the bone marrow becomes scarred and inflamed, creating a toxic environment that prevents healthy blood cells from forming. By combining Targeted Therapies—using parsaclisib to block PI3K-delta and ruxolitinib to block the JAK pathway—scientists are attempting to completely cool down this inflamed environment. This dual-blockade strategy aims to reverse or stop the scarring in the bone marrow, an approach that borrows heavily from the concepts of regenerative medicine and tissue healing in oncology.

Patient Management and Practical Recommendations

Patient safety is strictly guarded during clinical trials. Healthcare teams use rigorous rules to protect patients receiving parsaclisib.

Pre-treatment Tests to be Performed

• Comprehensive Blood Panel: To check liver function, kidney function, and ensure blood cell counts are safe enough to start.
• Infection Screening: Tests for hidden viruses (like Hepatitis B, Hepatitis C, or Cytomegalovirus) that could wake up while the immune system is suppressed.
• Lung Exam: A baseline assessment of the patient’s breathing and oxygen levels.

Precautions During Treatment

• Patients will need frequent hospital visits (often weekly or bi-weekly at the start) for blood draws.
• Patients should avoid receiving any “live” vaccines (like the MMR or yellow fever vaccine) during treatment, as their immune system cannot handle them safely.

“Do’s and Don’ts” List

• DO report any new or worsening diarrhea or stomach pain to your doctor the very same day. Do not try to treat it yourself.
• DO take your pill at the exact same time every day with a full glass of water.
• DO wash your hands frequently and avoid crowds to protect yourself from infections.
• DON’T ignore a fever (a temperature of 100.4°F / 38°C or higher) or a new cough; treat it as a medical emergency.
• DON’T start any new over-the-counter medicines, vitamins, or herbal supplements (especially St. John’s Wort) without asking your trial doctor, as they can interfere with how your body absorbs the drug.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Parsaclisib is an investigational drug and is not approved by the FDA, EMA, or other global regulatory bodies for commercial use outside of clinical trials. Always consult with your oncologist or a qualified healthcare provider regarding your specific medical condition, clinical trial eligibility, and available, approved treatment options.